

70th Anniversary Conference on ‘Vitamins in early development and healthy aging: impact on infectious and chronic disease’

Symposium 3: Vitamin D and immune function: from pregnancy to adolescence

Vitamin D and immune function: an overview

Martin Hewison

UCLA and Orthopaedic Hospital Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, David Geffen School of Medicine at UCLA, 615 Charles E. Young, Los Angeles, CA 90095, USA

Immunomodulatory actions of vitamin D have been recognised for over a quarter of a century, but it is only in the last few years that the significance of this to normal human physiology has become apparent. Two key factors have underpinned this revised perspective. Firstly, there are increasing data linking vitamin insufficiency with prevalent immune disorders. Improved awareness of low circulating levels of precursor 25-hydroxyvitamin D in populations across the globe has prompted epidemiological investigations of health problems associated with vitamin D insufficiency. Prominent among these are autoimmune diseases such as multiple sclerosis, type 1 diabetes and Crohn’s disease, but more recent studies indicate that infections such as tuberculosis may also be linked to low 25-hydroxyvitamin D levels. The second factor expanding the link between vitamin D and the immune system is our improved knowledge of the mechanisms that facilitate this association. It is now clear that cells from the immune system contain all the machinery needed to convert 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D, and for subsequent responses to 1,25-dihydroxyvitamin D. Mechanisms such as this are important for promoting antimicrobial responses to pathogens in macrophages, and for regulating the maturation of antigen-presenting dendritic cells. The latter may be a key pathway by which vitamin D controls T-lymphocyte (T-cell) function. However, T-cells also exhibit direct responses to 1,25-dihydroxyvitamin D, notably the development of suppressor regulatory T-cells. Collectively these observations suggest that vitamin D is a key factor linking innate and adaptive immunity, and both of these functions may be compromised under conditions of vitamin D insufficiency.

Vitamin D: Innate immunity: Antibacterial: Adaptive immunity

In 2008, Time magazine listed the ‘benefits of vitamin D’ as one of its top 10 medical breakthroughs for the previous year. Popular recognition such as this reflects the sea change in vitamin D physiology that has taken place over the last 5 years. Two pivotal concepts are central to our new perspective on vitamin D. The first stems from data suggesting that sub-optimal vitamin D status or vitamin D insufficiency is a prevalent health problem across the

globe⁽¹⁾. For many years, vitamin D status was broadly defined by whether or not the patient in question presented with rachitic bone disease (osteomalacia in adults). Using this guideline, serum levels of 25-hydroxyvitamin D (25OHD) <8 ng/ml (20 nm) were considered to represent vitamin D deficiency, with higher concentrations being viewed as ‘normal’. Based on these parameters the normal range for vitamin D status in adults was 8–30 ng/ml

Abbreviations: 25OHD, 25-hydroxyvitamin D; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; DBP, vitamin D binding protein; DC, dendritic cell; DEFB4, β-defensin 2; Gc, group-specific component; IBD, inflammatory bowel disease; NOD2, non-obese diabetic 2; PTH, parathyroid hormone; TB, tuberculosis; Treg, regulatory T-cells; Th1, type 1 T-helper; Th2, type 2 T-helper; TLR, Toll-like receptor; VDR, vitamin D receptor; VDRE, vitamin D response element.

Corresponding author: Professor Martin Hewison, fax +1 310 825 5409, email mhewison@mednet.ucla.edu

(20–75 nM). However, more recent studies have shown that classical physiological targets for vitamin D, circulating levels of parathyroid hormone (PTH)⁽²⁾, and intestinal Ca uptake⁽³⁾, continue to show correlation with serum 25OHD at levels as high as 30 ng/ml (75 nM). It has therefore been concluded that optimal serum 25OHD status is much higher than previously thought, with target concentrations of 30–32 ng/ml (75–80 nM) suggested as optimal⁽⁴⁾. As a consequence of this new perspective on adequate vitamin D levels, it has been suggested that sub-optimal vitamin D status, vitamin D insufficiency, is much more common than previously thought^(5,6).

The second research development that has redefined our perspective on vitamin D concerns the physiological impact of vitamin D insufficiency. Given the classical actions of vitamin D on Ca homeostasis and bone metabolism, it is likely that vitamin D insufficiency will exert some effects on the skeleton, although these may not be identical to the rachitic bone disease observed with classical vitamin D deficiency⁽¹⁾. However, recent studies have focused on the potential impact of impaired vitamin D status with respect to so-called ‘non-classical’ effects of vitamin D. These include anticancer⁽⁷⁾ and cardiovascular actions⁽⁸⁾, but prominent reports have also explored the association between vitamin D and the immune system^(9,10). The current review will focus specifically on the link between vitamin D and the immune system, with specific reference to the mechanisms by which variations in vitamin D status may play a pivotal role in defining specific types of immune response. The review will also describe the key health implications associated with vitamin D and human immunity, and the potential benefits this may offer when considering supplemental or therapeutic use of vitamin D.

Vitamin D physiology: classical and non-classical actions

Human subjects obtain most of their vitamin D through the action of sunlight on skin, with 7-dehydrocholesterol being converted photolytically to parental vitamin D in the epidermis. The vitamin D produced in the skin then undergoes sequential metabolic conversions. Firstly, in the liver to form 25OHD the main circulating form of vitamin D. The predominant enzyme involved in this 25-hydroxylation reaction has yet to be definitively identified but is likely to be the cytochrome P450, CYP2R1⁽¹¹⁾. Activation of 25OHD to the hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)₂D) is then catalysed by the enzyme 25OHD-1 α -hydroxylase (CYP27B1), which is located primarily in the proximal tubules of the kidney^(11,12). In classical vitamin D physiology, the 1,25(OH)₂D produced by the kidneys acts in an endocrine fashion to help regulate mineral homeostasis and bone metabolism (Fig. 1). Under conditions of low extracellular Ca, Ca-sensing receptors on parathyroid cells signal to increase the secretion of PTH by the parathyroid glands. The resulting rise in serum PTH up-regulates transcription of CYP27B1 in the proximal tubules leading to increased synthesis of active 1,25(OH)₂D. This activity is very sensitively regulated via two key mechanisms. The

first involves fibroblast growth factor 23, which is closely involved in the regulation of phosphate/Ca metabolism^(13–15). Fibroblast growth factor 23 acts mainly as a phosphaturic factor by inhibiting the expression of sodium-phosphate co-transporters in proximal tubular cells⁽¹⁶⁾, but it also suppresses production of 1,25(OH)₂D in the kidneys by inhibiting expression of CYP27B1, while stimulating the catabolic enzyme vitamin D-24 hydroxylase (CYP24A1)⁽¹⁷⁾. The latter is unique in the steroidogenic world in that it appears to function primarily as a ‘feedback’ control enzyme, limiting the tissue production of active 1,25(OH)₂D⁽¹⁸⁾.

After synthesis in the kidney, 1,25(OH)₂D is released into the general circulation and can then act on peripheral tissues. Target cell responses to 1,25(OH)₂D are dependent on expression of the intracellular vitamin D receptor (VDR), a member of the nuclear receptor superfamily⁽¹⁹⁾. When bound to 1,25(OH)₂D the VDR acts as a transcription factor by targeting vitamin D response element (VDRE) DNA motifs within gene promoters⁽²⁰⁾. The most well-recognised targets for VDR-mediated regulation of transcription include genes associated with Ca and phosphate uptake in the gastrointestinal tract, and those involved in the regulation of bone turnover in the skeleton^(19,20). VDR-mediated responses also provide another level of feedback control for the vitamin D system, with serum 1,25(OH)₂D acting to negatively regulate the production of PTH by the parathyroid glands⁽²⁰⁾. In addition to these classical actions, it has become increasingly clear that the same 1,25(OH)₂D–VDR complex can act to regulate expression of target genes not immediately involved in mineral homeostasis and bone metabolism. Prominent ‘non-classical’ responses to 1,25(OH)₂D include anti-proliferative/anticancer effects^(7,21), as well as effects on hypertension^(17,22,23) and immunomodulation^(10,24,25). A central feature of many of these non-classical actions of vitamin D is that, unlike effects on the skeleton, gut or parathyroid glands, the synthesis of active 1,25(OH)₂D appears to occur in a cell-specific manner, with CYP27B1 being expressed by many extra-renal tissues.

Extra-renal synthesis of 1,25-dihydroxyvitamin D

Extra-renal synthesis of 1,25(OH)₂D was initially identified in studies of patients with the granulomatous disease sarcoidosis, where macrophages from disease-affected tissues were shown to act as an extra-renal source of CYP27B1⁽²⁶⁾. In this instance, the localised production of 1,25(OH)₂D in peripheral tissues affected is sufficient to spill-over into the general circulation and, in some instances, promotes dysregulation of Ca homeostasis⁽²⁷⁾. Subsequent studies have shown that macrophage synthesis of 1,25(OH)₂D is common to granulomatous diseases in general, as well as several types of tumour involving significant macrophage infiltration⁽²⁸⁾. However, expression of CYP27B1 has also been reported for other extra-renal tissues in the absence of any disease⁽²⁹⁾.

Historically, the placenta was one of the first extra-renal tissues shown to be capable of synthesising 1,25(OH)₂D, with activation of 25OHD being detectable in both




Fig. 1. (Colour online) Renal and extra-renal metabolism of vitamin D. Schematic representation showing key pathways associated with the metabolism and action of vitamin D in normal renal physiology and in extra-renal tissues. The vitamin D-activating enzyme 25-hydroxyvitamin D (25OHD)-1 α -hydroxylase (CYP27B1) is expressed in the kidney proximal tubules. Renal CYP27B1 is induced by parathyroid hormone (PTH), and converts 25OHD to 1,25-dihydroxyvitamin D (1,25(OH)₂D). The latter is released into the blood stream and also induces renal vitamin D-24-hydroxylase (CYP24A1) activity, leading to feedback synthesis of the less active metabolites, 1,24,25-trihydroxyvitamin D (1,24,25(OH)₃D) and 24,25-dihydroxyvitamin D (24,25(OH)₂D). Raised serum 1,25(OH)₂D acts on distal target organs to: suppress synthesis of PTH by the parathyroid glands; modulate bone-forming osteoblasts (OB) and bone-resorbing osteoclasts (OC) in the skeleton; enhance phosphate and Ca uptake in the intestine. 1,25(OH)₂D also stimulates expression of fibroblast growth factor 23 (FGF23), which suppresses renal CYP27B1 activity. Documented extra-renal sites for expression of CYP27B1 are shown, along with putative actions of locally synthesised 1,25(OH)₂D within these tissues.

maternal decidua and fetal trophoblast^(30,31). Since then studies of the spatio-temporal organisation of placental CYP27B1 across gestation, has shown that the enzyme is induced early in pregnancy in both decidua and trophoblastic cells but then declines in the third trimester of pregnancy^(32,33). Expression of the VDR is also induced in parallel with CYP27B1, consistent with a localised function vitamin D in the placenta, with 1,25(OH)₂D synthesised by decidual or trophoblastic cells acting in an autocrine or paracrine fashion⁽³³⁾. This mechanism is therefore similar to that conventionally described for expression of CYP27B1 and VDR within cells from the immune system⁽¹⁰⁾. The importance of decidual/trophoblast expression of CYP27B1 as an extra-renal feature of the vitamin D system during pregnancy is emphasised by studies of the CYP27B1 knockout mouse. In this animal model, the CYP27B1 gene is replaced with a β -galactosidase reporter construct linked to the endogenous gene promoter for CYP27B1. As a result, transcription of CYP27B1 can be visualised in tissues from the knockout mouse simply by staining for β -galactosidase activity⁽³⁴⁾. Using this approach, it was possible to confirm expression

of CYP27B1 in classical sites of 1,25(OH)₂D production, such as the kidney, but transcription of the enzyme was also strongly detected in the placenta⁽³⁴⁾.

The capacity for efficient synthesis of 1,25(OH)₂D is further enhanced by studies showing that the vitamin D catabolic enzyme CYP24A1 is poorly expressed in the placenta during early stages of gestation⁽³³⁾. The explanation for this appears to be that CYP24A1 gene is highly methylated in the placenta, resulting in tissue-specific silencing of its transcription⁽³⁵⁾. This effect appears to be very selective, and suggests that the placenta is one of the few tissues in which feedback regulation of 1,25(OH)₂D is absent⁽³⁵⁾. The net effect of enhanced expression of CYP27B1 in proximity to low or absent CYP24A1 activity is likely to be enhanced concentrations of 1,25(OH)₂D in the placenta. It is possible that these elevated levels of 1,25(OH)₂D will be sufficient to spill-over into the fetal or maternal circulation. This may provide a mechanism for the increased serum levels of 1,25(OH)₂D that are characteristic of pregnant women⁽³⁶⁾. However, current studies suggest that placental CYP27B1 activity also plays a pivotal role in mediating localised responses to vitamin D.

In particular, it has been suggested that expression of CYP27B1 in the placenta is crucial to antibacterial and anti-inflammatory responses at the fetal–maternal interface⁽³³⁾.

The placenta provides an excellent example of the potential importance of extra-renal 1,25(OH)₂D production to normal physiology. However, expression of VDR and CYP27B1 has been reported for many other tissues that can be broadly termed ‘barrier sites’^(37,38), indicating that localised responses to vitamin D may be a key feature of these tissues (see Fig. 1). These include the skin, lungs and colon where the function of localised synthesised 1,25(OH)₂D does not appear to be directly linked to classical vitamin D endocrinology. Instead, attention has turned to the possible impact of CYP27B1 and VDR components of ‘non-classical’ responses to vitamin D. As illustrated in Fig. 1, this includes anti-proliferative/anticancer effects^(39,40), as well as potential actions on the regulation of blood pressure⁽⁴¹⁾. In addition, much recent attention has focused on the proposed role of vitamin D as an immunomodulatory factor and this is outlined in further detail in the following sections.

Vitamin D and innate antibacterial immunity

It is now more than a quarter of a century since a study was published showing that 1,25(OH)₂D potently suppressed proliferation of the infectious pathogen *Mycobacterium tuberculosis* (*M. tuberculosis*) in human monocytes⁽⁴²⁾. At the time, the physiological significance of this was unclear. It was known that patients with tuberculosis (TB) often presented with over-production of 1,25(OH)₂D^(43,44) in a similar fashion to that described earlier for sarcoidosis. However, this was not initially linked to the ability of monocyte CYP27B1 activity to support intracrine killing of *M. tuberculosis*. Rather it was assumed that therapeutic administration of 1,25(OH)₂D or synthetic non-calcaemic analogues of 1,25(OH)₂D would provide the most effective conduit for translational use of vitamin D in patients with TB. Surprisingly, it was not until 2006 that this issue was resolved in a series of studies documenting the induction of CYP27B1 in human monocytes treated with immunogens corresponding to *M. tuberculosis*. Data by Liu *et al.* showed for the first time that localised synthesis of 1,25(OH)₂D by monocytes was an integral part of the normal innate immune function of these cells. Gene array analyses showed that macrophage expression of CYP27B1 and VDR was induced following activation of Toll-like receptor (TLR) 2/1, a pathogen recognition receptor for Gram-positive bacteria and *M. tuberculosis*⁽⁴⁵⁾. These observations were consistent with a localised, intracrine system for vitamin D responses in *M. tuberculosis*-challenged monocytes, and this was confirmed by subsequent studies in which TLR2/1-activated cells were treated with 25OHD. Under these conditions, the resulting locally synthesised 1,25(OH)₂D acted to modulate expression of VDR target genes such as CYP24A1. However, intracrine synthesis of 1,25(OH)₂D also induced expression of the gene for cathelicidin (LL-37), which encodes a protein known to be involved in

promoting intracellular killing of bacteria^(46,47). Earlier studies indicated that transcription of LL-37 is stimulated in a direct fashion by the 1,25(OH)₂D–VDR complex⁽⁴⁸⁾ acting via a specific VDRE within the LL-37 gene promoter⁽⁴⁹⁾. Interestingly, this VDRE appears to be specific for primates, and vitamin D does not appear to induce expression of LL-37 in other lower mammals such as mice^(49,50).

The most notable observation from studies of the intracrine induction of monocyte LL-37 is that this response led to enhanced bacterial killing simply by increasing levels of the precursor form of vitamin D, 25OHD. Consequently, it was proposed that simple variations in vitamin D status could enhance or impair monocyte innate immune responses to infection. This was illustrated by studies showing that monocytes cultured in medium supplemented with serum from vitamin D-insufficient donors produced lower levels of LL-37 following TLR2/1 activation when compared with cells cultured in serum from vitamin D-sufficient donors⁽⁴⁵⁾. In a similar fashion, serum from vitamin D insufficient subjects supported higher levels of TLR2/1-induced LL-37 following *in vivo* supplementation with vitamin D⁽⁵¹⁾. The overall conclusion from these observations was that vitamin D is an important component of antibacterial activity in monocytes. As such, decreased availability of serum 25OHD due to vitamin D insufficiency has the potential to cause impaired innate immune response to infection.

Since these initial studies, the intracrine model for vitamin D-mediated antibacterial function in monocytes has been expanded to include other mechanisms that further facilitate the immune activity of vitamin D (see Fig. 2). For example, it is now clear that LL-37 is not the only antibacterial target for vitamin D in monocytes. The gene promoter for another antibacterial protein β -defensin 2 (DEFB4) is known to contain VDRE in a similar fashion to LL-37⁽⁴⁸⁾, but initially did not appear to be stimulated by 1,25(OH)₂D⁽⁴⁵⁾. However, more recent data have demonstrated 1,25(OH)₂D–VDR induction of DEFB4 in conjunction with activation of another transcription factor, NF- κ B. Induction of NF- κ B following treatment of monocytes with cytokines such as IL-1 β ⁽⁵²⁾ or as a consequence of signalling via the intracellular pathogen recognition receptor non-obese diabetic 2 (NOD2)⁽⁵³⁾, have been shown to enhance 1,25(OH)₂D-mediated induction of DEFB4. Vitamin D has also been shown to promote the environment in which monocytes carry out bacterial killing. Monocytes treated with 1,25(OH)₂D show increased levels of autophagy, an intracellular mechanism known to be essential for the general cytoplasmic homeostasis in eukaryotes⁽⁵⁴⁾. Autophagy and formation of associated autophagosomes are also known to be important as a mechanism for intracellular isolation of pathogens and their subsequent eradication by antibacterial proteins⁽⁵⁵⁾. Vitamin D-mediated induction of autophagosomes in monocytes is associated with enhanced capacity for intracellular killing of *M. tuberculosis*, but appears to be mediated indirectly via increased transcription of LL-37⁽⁵⁶⁾. Subsequent studies have shown that, consistent with the initial studies of intracrine *M. tuberculosis* induction of LL-37, TLR2/1-mediated induction of autophagy appears




Fig. 2. (Colour online) Vitamin D and monocyte antibacterial activity. Monocyte Toll-like receptor (TLR2) signalling results in transcriptional induction of the vitamin D receptor (VDR) and 1α -hydroxylase (CYP27B1). Circulating 25-hydroxyvitamin D (25OHD) bound to serum vitamin D binding protein (DBP) enters monocytes and is converted to 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}$) by mitochondrial CYP27B1. VDR-bound $1,25(\text{OH})_2\text{D}$ is then able to act as a transcriptional factor, inducing expression of cathelicidin (LL-37) and β -defensin 2 (DEFB4) (the latter in conjunction with NF- κ B). $1,25(\text{OH})_2\text{D}$ -induced LL-37 promotes autophagy (LC3 expression) and the formation of autophagosomes. Expression of CYP27B1 is also stimulated by the cytokines IL-15 and interferon γ ($\text{IFN}\gamma$). Conversely, monocyte synthesis of $1,25(\text{OH})_2\text{D}$ is suppressed by IL-4, which acts to promote catabolic CYP24A1 activity. $1,25(\text{OH})_2\text{D}$ produced by monocytes may also act on other immune cells, notably those from the adaptive immune system.

to involve induction of 25OHD metabolism via CYP27B1⁽⁵⁷⁾, suggesting that this mechanism will also be highly influenced by changes in vitamin D status.

Induction of antibacterial activity by vitamin D metabolites is not restricted to monocytes and macrophages. Vitamin D-mediated induction of LL-37 has been reported for a variety of cell types including bronchial epithelial cells⁽⁵⁸⁾, myeloid cell lines⁽⁴⁹⁾, decidual⁽⁵⁹⁾ and trophoblastic cells of the placenta⁽⁶⁰⁾. However, this response is not universal⁽⁶¹⁾, and in those cells that do show induction of LL-37 by vitamin D, the precise mechanism may be different to that shown in Fig. 2. For example, human keratinocytes have relatively low expression of TLR2 and are therefore less sensitive to ligands for this pathogen recognition receptor⁽⁶²⁾. In this setting, other tissue-specific factors such as transforming growth factor- β can act to compensate. Transforming growth factor- β potently stimulates CYP27B1 expression in keratinocytes, leading to increased levels of $1,25(\text{OH})_2\text{D}$ in the skin. This, in turn, stimulates TLR expression, leading to enhanced sensitivity to TLR2 ligands leading ultimately to further elevation of epidermal CYP27B1 and enhanced vitamin D-mediated production of antimicrobial LL-37⁽⁶²⁾. Because transforming growth factor- β is released in the skin following epidermal wounding, it has been suggested that vitamin

D-induced LL-37 may provide a mechanism for the prevention of infection following wounding. Another recently reported mechanism that appears to enhance vitamin D-mediated antibacterial activity is signalling via the intracellular pathogen-recognition receptor NOD2. Expression of NOD2 is potently induced by $1,25(\text{OH})_2\text{D}$ in a variety of cell types, enhancing cell sensitivity to the NOD2 ligand muramyl dipeptide, a product of Gram-positive and Gram-negative bacteria⁽⁶³⁾. NOD2 activates NF- κ B, and this has been shown to potentiate vitamin D-mediated transcription of LL-37 and DEFB4⁽⁶³⁾. Similar NF- κ B-potential of vitamin D-induced DEFB4 has also been described for IL-1 β , suggesting that cytokines from other parts of the normal immune system may act to fine tune innate antibacterial responses to vitamin D.

Vitamin D, antigen presentation and innate immunity

Effective management of infection not only involves adequate innate immune management of intracellular bacteria but also requires appropriate adaptive or acquired immune activity. At the interface between these two mechanisms are antigen-presenting cells, which present bacterial antigens to cells from the adaptive immune system such as

T-lymphocytes (T-cells). Macrophages are able to fulfil this function, but antigen presentation is more effectively executed by dendritic cells (DC). It was recognised many years ago that DC isolated from lymphoid tissue express VDR⁽⁶⁴⁾, indicating that they were a likely target for vitamin D-mediated immunoregulation. This was confirmed by studies showing that treatment with 1,25(OH)₂D suppressed DC maturation and thereby promoted a tolerogenic phenotype^(65,66). This effect was more pronounced in myeloid DC relative to plasmacytoid DC, despite both subsets expressing similar levels of VDR⁽⁶⁷⁾. Under steady state conditions myeloid DC are more active at priming naive T-cell responses. By contrast plasmacytoid DC exhibit more tolerogenic, immunosuppressive properties. Consequently, 1,25(OH)₂D appears to fulfil a more tolerogenic function by suppressing activity of myeloid DC, while leaving the already tolerogenic plasmacytoid DC unaffected.

DC share the same cell lineage as monocytes and macrophages, and show the similar patterns of VDR and CYP27B1 expression⁽⁶⁸⁾. Consequently, studies using monocyte-derived DC showed that both 1,25(OH)₂D and 25OHD are able to suppress the maturation and function of these cells⁽⁶⁸⁾. Differentiation of DC towards a mature, antigen-presenting phenotype, leads to increased expression of CYP27B1 but with a reciprocal suppression of VDR levels⁽⁶⁸⁾. It therefore seems likely that any 1,25(OH)₂D produced by mature DC will not act in an intracrine fashion due to low VDR levels. Instead a paracrine mechanism is more likely with VDR-rich immature DC responding to 1,25(OH)₂D produced by VDR-depleted mature DC. This mechanism may be important because it enables some DC to mature thereby facilitating activation of normal immune responses, while preventing exaggeration of this response and possible pathological effects. The importance of vitamin D as a modulator of DC function is supported by studies of VDR and CYP27B1 gene knockout mice, in which these animals present with lymphatic abnormalities consistent with increased numbers of mature DC^(69,70) and aberrant DC trafficking⁽⁷¹⁾.

Vitamin D, innate immunity and human disease

Irrespective of recent developments in the intracrinology of innate immunity, there is an historical precedence linking vitamin D and infectious disease. In 1903, Niels Finsen received the Nobel Prize for Medicine after he demonstrated that he could cure Lupus Vulgaris (the epidermal form of TB) with exposure to light from an electric arc lamp. In a similar fashion, cod liver oil, a rich source of dietary vitamin D was also used as a treatment for TB⁽⁷²⁾. With this in mind, and the recent studies showing TLR2/1 activation of monocyte vitamin D metabolism, it is not surprising that translation studies have explored further the link between vitamin D and the disease TB. Epidemiology has shown that vitamin D-insufficiency (serum 25OHD <75 nm) is associated with increased incidence of TB^(73–76). Several clinical trials of vitamin supplementation have also been reported with varying success^(76–78). The most recent supplementation study using 4 × 2.5 mg

vitamin D was successful in raising serum levels of 25OHD in TB patients, but showed no overall difference in sputum conversion time between treatment and placebo groups⁽⁷⁹⁾. However, the authors did show a significant improvement in sputum conversion in a specific subset of TB patients with a *Taq1* single nucleotide polymorphism within the VDR gene⁽⁷⁹⁾. Thus inherited factors may influence responses to vitamin D supplementation and this facet of vitamin D physiology. Another example of this is provided by the gene for vitamin D binding protein (DBP), the main serum carrier of vitamin D metabolites. Recent studies by our group have shown that the ability of 25OHD or 1,25(OH)₂D to stimulate antibacterial activity in monocytes is affected by serum levels of DBP and its binding affinity for vitamin D metabolites⁽⁸⁰⁾. Both of these parameters are influenced by DBP genotype, notably the alleles referred to as group-specific component (Gc)IF, Gc1S and Gc2^(81,82). Data from our studies suggest that there is greater bioavailability of 25OHD or 1,25(OH)₂D in the presence of low affinity forms of DBP such as Gc1S and Gc2⁽⁸⁰⁾. This observation supports the ‘free hormone hypothesis’ in which steroid hormones are able to passively diffuse across cell membranes when they are not bound to carrier proteins. However, it is important to recognise that the opposite scenario, binding of 25OHD to DBP, is important for classical vitamin D endocrinology. DBP-bound 25OHD is recovered from glomerular filtrates via an endocytic mechanism involving the membrane receptor megalin prior to its conversion to 1,25(OH)₂D in the proximal tubules⁽⁸³⁾.

The link between vitamin D and infection is unlikely to be restricted to TB. Serum levels of 25OHD have been shown to correlate with circulating levels of LL-37 and increased risk of critical illness in patients with sepsis⁽⁸⁴⁾. Low vitamin D status has also been linked to increased infection and mortality in chronic kidney disease⁽⁸⁵⁾, and seasonal variations of infections such as influenza, the latter highlighting a potential role for vitamin D in counteracting infection in the upper respiratory tract⁽⁸⁶⁾. However, it is also important to recognise that the innate immune regulatory effects of vitamin D may not be restricted to infectious disease. For example, vitamin D-deficient mice show suppressed colonic expression of angiogenin-4, an antimicrobial protein produced primarily in Paneth cells which acts to minimise tissue invasion by enteric bacteria⁽⁸⁷⁾. In view of the fact that aberrant innate immune response to enteric bacteria has been postulated to initiate tissue inflammation in some types of inflammatory bowel disease (IBD)⁽⁸⁸⁾, it is possible to speculate a role for vitamin D in protecting against this disease via the induction of angiogenin-4 antibacterial responses to enteric bacteria within the gastrointestinal tract. Finally, vitamin D may also play a role in promoting innate immune responses to non-living material. Studies using monocytes obtained from patients with Alzheimer’s disease have shown that these cells are less able to phagocytose and degrade β-amyloid protein⁽⁸⁹⁾. Treatment with 1,25(OH)₂D potently enhanced monocyte phagocytosis and degradation of β-amyloid, suggesting a role for vitamin D-mediated immunity in this neurological disorder.




Fig. 3. Vitamin D and T-cell function. Under conditions of vitamin D sufficiency, synthesis of 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}$) within the immune system acts to maintain a tolerogenic immune response by favouring Th2 and Treg v. Th1 and Th17 cells. Conversely, vitamin D insufficiency will favour a more inflammatory immune response involving Th1/Th17 cells rather than Th2/Treg.

Vitamin D and adaptive immunity

Although much of the recent interest in non-classical vitamin D action has stemmed from studies of monocyte antibacterial activity, it is clear that there are many other links between vitamin D and the immune system. For example, immune responses to pathogens such as *M. tuberculosis* are not restricted simply to TLR2/1-induced expression of LL-37 or DEFBA4, but instead involve other facets of immunity. Promoter-reporter analysis of the transcriptional regulation of CYP27B1 suggests that TLR-mediated induction of the enzyme involves JAK-STAT (Janus kinase-signal transducer and activator of transcription), mitogen-activated protein kinase and NF- κ B pathways, but these signalling pathway also synergise with cytokine-mediated induction of CYP27B1^(90,91). In particular, recent studies have shown that cytokines from different T-cell subsets exert very specific effects on innate immune responses to vitamin D. Interferon γ , a cytokine produced by type 1 T-helper (Th1) cells potently enhances TLR2/1-induced expression of CYP27B1 and associated bacterial killing⁽⁹²⁾. By contrast IL-4 a cytokine produced by type 2 T-helper (Th2) cells acts to attenuate TLR2/1-activated bacterial killing. However, in this instance, the action of IL-4 was not due to effects on CYP27B1, but instead involved enhanced CYP24A1 activity⁽⁹²⁾. In view of this divergence between effects of Th1 and Th2 cytokines on monocyte 25OHD metabolism, it is interesting to speculate that vitamin D may play a key role at the boundary between the innate and adaptive immune systems. What is certainly clear is the independent of its innate immune activity vitamin D can act as a potent regulator of the adaptive immune system as well⁽⁹⁵⁾.

One of the initial observations linking vitamin D with the adaptive immune system was that T-cells and B-lymphocytes (B-cells) express VDR^(94,95), with these levels increasing as T- or B-cells proliferate⁽⁹⁶⁾. As a consequence, initial studies of the effects of vitamin D on T-cells focused on the ability of $1,25(\text{OH})_2\text{D}$ to suppress T-cell proliferation^(96–98). However, subsequent studies showed that vitamin D could also influence the phenotype of T-cells, notably through inhibition of Th1 cells, a subset of CD4^+ effector T-cells closely associated with cellular immune responses⁽⁹⁹⁾. In concert with this $1,25(\text{OH})_2\text{D}$ was also shown to enhance cytokines associated with Th2

cells, a subset of CD4^+ T-cells associated with humoral immunity^(100,101). It was therefore suggested that vitamin D could help limit the tissue damage associated with excessive Th1 cellular immune responses by switching T-cells to a Th2 phenotype. Subsequent studies using VDR gene knockout mice have questioned the validity of this hypothesis in that these animals have reduced rather than elevated levels of Th1 cells⁽¹⁰²⁾. Thus, although vitamin D appears to promote a Th1 to Th2 shift *in vitro*, it seems likely that its effects on T-cells *in vivo* are more complex. More recent reports have shown that in addition to Th1 or Th2 cells, there is a third effector T-cell population termed Th17 cells because of their capacity to synthesise IL-17^(103,104). Th17 cells are important for promoting immune responses to some pathogens, but they have also been linked to inflammatory tissue damage^(105,106). Treatment of T-cells *in vitro* with $1,25(\text{OH})_2\text{D}$ suppresses Th17 development^(107,108), and inhibits of IL-17 production via a post-transcriptional mechanism⁽¹⁰⁹⁾. In a similar fashion, *in vivo* mouse models of IBD have shown that treatment with $1,25(\text{OH})_2\text{D}$ down-regulates expression of IL-17⁽¹¹⁰⁾. By contrast, loss of $1,25(\text{OH})_2\text{D}$ *in vivo* as a result of CYP27B1 gene knockout leads to elevated levels of IL-17⁽¹¹¹⁾.

The adaptive immune effects of vitamin D are not restricted to effector T-cells, and also include actions on suppressor or regulatory T-cells (Treg), a group of CD4^+ T-cells known to inhibit the proliferation of other CD4^+ T-cells. Treatment of naive CD4^+ T-cells with $1,25(\text{OH})_2\text{D}$ potently induces the development of Treg⁽¹¹²⁾, and this may exert beneficial effects in autoimmune disease and host-graft rejection^(113–115). Although, $1,25(\text{OH})_2\text{D}$ can stimulate Treg development directly via VDR expression by CD4^+ T-cells^(116,117), it may also act via effects on antigen-presenting cells. Specifically, as outlined earlier, the ability of $1,25(\text{OH})_2\text{D}$ to induce an immature DC phenotype will promote tolerogenic Treg activity in CD4^+ T-cells^(118–120). In view of the fact that DC express CYP27B1 as well as VDR, this indirect mechanism for inducing Treg is also likely to be stimulated by 25OHD, providing a possible link between low serum vitamin D status and impaired Treg activity⁽²⁸⁾. The overall conclusion from the various studies of T-cell phenotype is that vitamin D acts to maintain a balance between inflammatory Th1/Th17 cells and immunosuppressive Th2/Treg (Fig. 3).

In common with CD4^+ effector T-cells, CD8^+ cytotoxic T-cells express abundant VDR and are sensitive to cytokine regulation by $1,25(\text{OH})_2\text{D}$ ⁽¹²¹⁾, but when compared with CD4^+ T-cells they are relatively insensitive to anti-proliferative responses^(122,123). The physiological relevance of $1,25(\text{OH})_2\text{D}$ responses in CD8^+ T-cells remains unclear. For example, $1,25(\text{OH})_2\text{D}$ can protect against the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis⁽¹²⁴⁾. However, this effect does not appear to require the presence of CD8^+ cells despite the fact that these cells have been implicated in multiple sclerosis and experimental autoimmune encephalomyelitis disease pathophysiology⁽¹²⁵⁾. Effects of vitamin D on CD8^+ T-cells may be subset-specific. The CD8 molecule on T-cells can be expressed as either an

α - β heterodimer or as an α - α homodimer, and the latter appear to be influenced by vitamin D. Studies using the VDR gene knockout mouse have shown aberrant gut migration of CD8⁺ α - α cells and this appears to be linked to increased risk of IBD in these animals⁽¹²⁶⁾. This is similar to the positive effect of 1,25(OH)₂D on epidermal T-cell homing⁽¹²⁷⁾, but contrasts its negative effects on T-cell homing to lymph nodes⁽¹²⁸⁾.

Early studies demonstrated that 1,25(OH)₂D could also act on VDR-expressing B-cells to suppress cells proliferation⁽¹²⁹⁾ and Ig production⁽¹³⁰⁾. More recent reports confirmed these effects and also showed that 1,25(OH)₂D can also inhibit the differentiation of plasma cells and class-switched memory cells⁽¹³¹⁾, highlighting a potential role for vitamin D in B-cell-related disorders such as systemic lupus erythematosus. Interestingly, this study also demonstrated B-cell expression of CYP27B1, indicating that B-cells may be capable of autocrine/intracrine responses to vitamin D⁽¹³¹⁾. This mechanism may be common to lymphocytes in general as CYP27B1 expression has also been reported in T-cells⁽¹²⁷⁾.

Vitamin D, adaptive immunity and human disease

Although the adaptive immune system is essential for much of the innate immune activity outlined in previous sections, it clear that vitamin D may also be linked to diseases more closely associated with T- and B-cell function. In particular, increasing numbers of studies have linked vitamin D insufficiency to increased risk or severity of autoimmune disease^(132,133). Low vitamin D status has been linked to type 1 diabetes^(134,135), and supplementation with vitamin D has been reported to protect against this disease⁽¹³⁶⁾. In a similar fashion, analysis of the NOD mouse, an animal model for type 1 diabetes, has shown increased disease severity under conditions of dietary vitamin D restriction⁽¹³⁷⁾. Another strand of evidence linking vitamin D with type 1 diabetes is provided by the extensive genetic analyses that have investigated the physiological impact of polymorphic variations in the genes for various components of the vitamin D metabolic and signalling system. Specific VDR gene haplotypes appear to protect against diabetes⁽¹³⁸⁾, and polymorphisms in the CYP27B1 gene have also been shown to affect diabetes susceptibility⁽¹³⁹⁾.

Other autoimmune diseases linked to vitamin D insufficiency include multiple sclerosis (reviewed in⁽¹⁴⁰⁾). Studies of human multiple sclerosis patients are supported by analysis of the experimental autoimmune encephalomyelitis mouse of multiple sclerosis, which shows increased disease severity under dietary vitamin D restriction⁽¹⁴¹⁾. Therapeutic administration of 1,25(OH)₂D to experimental autoimmune encephalomyelitis mice has been shown to protect against disease symptoms^(142,143), with this effect involving regulation of cytokine synthesis, notably IL-10 activity, and apoptosis of inflammatory cells⁽¹¹⁵⁾. In a similar fashion to type 1 diabetes and multiple sclerosis, epidemiology suggests that patients with Crohn's disease, a form of IBD have decreased serum levels of 25OHD⁽¹⁴⁴⁻¹⁴⁶⁾. Likewise, studies using various

experimentally induced forms of IBD in mice indicate that 1,25(OH)₂D plays a crucial role in the pathophysiology of this disease^(111,147-149). Crohn's disease is considered to be an autoimmune disease, with the disease aetiology appearing to be due to aberrant colonic immune responses to enteric bacteria. Intriguingly, current studies have implicated aberrant innate immune handling of enteric microbiota as an initiator of the adaptive immune damage associated with Crohn's disease⁽⁸⁸⁾. Consequently, it is possible that the effects of vitamin D on IBD may involve both the activation of innate immunity, together with the suppression of adaptive immunity and associated inflammation.

Conclusions

Although the interaction between vitamin D and the immune system has been recognised for almost 30 years, it is only in the last few years that the physiological relevance of vitamin D-mediated immunity has become clear. Studies using human cells and animal models have highlighted potent effects of vitamin D on both innate and adaptive immune responses in a wide variety of tissues. These observations support the overall hypothesis that vitamin D may play a role in promoting elimination of pathogens such as *M. tuberculosis*, while suppressing the potentially damaging effects of prolonged inflammation. As such, vitamin D has the potential to influence a wide range of immune disorders, notably infectious and autoimmune diseases. At a clinical level, associated studies have expanded functional data to show that vitamin D insufficiency is linked to several common immune health problems.

Many challenges remain. For example, innate antibacterial activity of vitamin D appears to be restricted to primates, which express the promoter VDRE required for vitamin D-mediated transcriptional regulation of antibacterial proteins. This raises the question as to whether or not vitamin D plays a role in innate immunity in mouse models? Some mouse antimicrobial molecules such as angiogenin-4 appear to be influenced by vitamin D⁽¹⁵⁰⁾, but are there other targets? In contrast to the innate immune system, most of the reported actions of vitamin D on adaptive immunity are focused on suppressive actions. However, recent studies suggest that vitamin D may also be involved in directing T-cell activation⁽¹⁵¹⁾. Although this mechanism is considered to be controversial⁽¹⁵²⁾, it underlines the exciting new developments that characterise the current interest in vitamin D and the immune system. Perhaps the most important challenge facing vitamin D immunity research is the evolution of clinical studies from observational association analyses to prospective clinical trials. For many diseases, notably autoimmune diseases, this is a huge logistical challenge and is complicated by uncertainty over whether vitamin D can be used as therapy for some diseases or whether it simply acts to protect against the onset of disease.

Acknowledgements

The author declares no conflict of interest.

References

1. Holick MF (2007) Vitamin D deficiency. *N Engl J Med* **357**, 266–281.
2. Chapuy MC, Preziosi P, Maamer M *et al.* (1997) Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* **7**, 439–443.
3. Heaney RP, Dowell MS, Hale CA *et al.* (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. *J Am Coll Nutr* **22**, 142–146.
4. Holick MF (2009) Vitamin D status: Measurement, interpretation, and clinical application. *Ann Epidemiol* **19**, 73–78.
5. Mithal A, Wahl DA, Bonjour JP *et al.* (2009) Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int* **20**, 1807–1820.
6. Dawson-Hughes B, Heaney RP, Holick MF *et al.* (2005) Estimates of optimal vitamin D status. *Osteoporos Int* **16**, 713–716.
7. Spina CS, Tangpricha V, Uskokovic M *et al.* (2006) Vitamin D and cancer. *Anticancer Res* **26**, 2515–2524.
8. Zittermann A (2006) Vitamin D and disease prevention with special reference to cardiovascular disease. *Prog Biophys Mol Biol* **92**, 39–48.
9. Adams JS & Hewison M Update in vitamin D. *J Clin Endocrinol Metab* **95**, 471–478.
10. Adams JS & Hewison M (2008) Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. *Nat Clin Pract Endocrinol Metab* **4**, 80–90.
11. Schuster I (2011) Cytochromes P450 are essential players in the vitamin D signaling system. *Biochim Biophys Acta* **1814**, 186–199.
12. Zehnder D, Bland R, Walker EA *et al.* (1999) Expression of 25-hydroxyvitamin D₃–1 α -hydroxylase in the human kidney. *J Am Soc Nephrol* **10**, 2465–2473.
13. Liu S & Quarles LD (2007) How fibroblast growth factor 23 works. *J Am Soc Nephrol* **18**, 1637–1647.
14. Yamazaki Y, Tamada T, Kasai N *et al.* (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. *J Bone Miner Res* **23**, 1509–1518.
15. Yoshiko Y, Wang H, Minamizaki T *et al.* (2007) Mineralized tissue cells are a principal source of FGF23. *Bone* **40**, 1565–1573.
16. Fukumoto S (2008) Physiological regulation and disorders of phosphate metabolism – pivotal role of fibroblast growth factor 23. *Intern Med* **47**, 337–343.
17. Razaque MS (2009) Does FGF23 toxicity influence the outcome of chronic kidney disease? *Nephrol Dial Transplant* **24**, 4–7.
18. Omdahl JMB (2005) *The 25-hydroxyvitamin D-24-hydroxylase*. New York: Elsevier.
19. Haussler MR, Haussler CA, Bartik L *et al.* (2008) Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention. *Nutr Rev* **66**, S98–S112.
20. Jurutka PW, Bartik L, Whitfield GK *et al.* (2007) Vitamin D receptor: Key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. *J Bone Miner Res* **22**, Suppl 2, V2–V10.
21. Holick MF (2006) Vitamin D: Its role in cancer prevention and treatment. *Prog Biophys Mol Biol* **92**, 49–59.
22. Zhou C, Lu F, Cao K *et al.* (2008) Calcium-independent and 1,25(OH)₂D₃-dependent regulation of the renin-angiotensin system in 1 α -hydroxylase knockout mice. *Kidney Int* **74**, 170–179.
23. Li YC, Kong J, Wei M *et al.* (2002) 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* **110**, 229–238.
24. Hewison M (2011) Vitamin D and innate and adaptive immunity. *Vitam Horm* **86**, 23–62.
25. Hewison M Antibacterial effects of vitamin D. *Nat Rev Endocrinol* **7**, 337–345.
26. Adams JS & Gacad MA (1985) Characterization of 1 α -hydroxylation of vitamin D₃ sterols by cultured alveolar macrophages from patients with sarcoidosis. *J Exp Med* **161**, 755–765.
27. Papapoulos SE, Clemens TL, Fraher LJ *et al.* (1979) 1,25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. *Lancet* **1**, 627–630.
28. Hewison M, Burke F, Evans KN *et al.* (2007) Extra-renal 25-hydroxyvitamin D₃–1 α -hydroxylase in human health and disease. *J Steroid Biochem Mol Biol* **103**, 316–321.
29. Zehnder D, Bland R, Williams MC *et al.* (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1 α -hydroxylase. *J Clin Endocrinol Metab* **86**, 888–894.
30. Gray TK, Lester GE & Lorenc RS (1979) Evidence for extra-renal 1 α -hydroxylation of 25-hydroxyvitamin D₃ in pregnancy. *Science* **204**, 1311–1313.
31. Weisman Y, Harell A, Edelstein S *et al.* (1979) 1 α ,25-Dihydroxyvitamin D₃ and 24,25-dihydroxyvitamin D₃ *in vitro* synthesis by human decidua and placenta. *Nature* **281**, 317–319.
32. Zehnder D, Evans KN, Kilby MD *et al.* (2002) The ontogeny of 25-hydroxyvitamin D(3) 1 α -hydroxylase expression in human placenta and decidua. *Am J Pathol* **161**, 105–114.
33. Evans KN, Bulmer JN, Kilby MD *et al.* (2004) Vitamin D and placental-decidual function. *J Soc Gynecol Investig* **11**, 263–271.
34. Vanhooke JL, Prah J, Kimmel-Jehan C *et al.* (2006) CYP27B1 null mice with LacZ reporter gene display no 25-hydroxyvitamin D₃–1 α -hydroxylase promoter activity in the skin. *Proc Natl Acad Sci USA* **103**, 75–80.
35. Novakovic B, Sibson M, Ng HK *et al.* (2009) Placenta-specific methylation of the vitamin D 24-hydroxylase gene: Implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. *J Biol Chem* **284**, 14838–14848.
36. Kovacs CS & Kronenberg HM (1997) Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. *Endocr Rev* **18**, 832–872.
37. Jones G, Strugnell SA & DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. *Physiol Rev* **78**, 1193–1231.
38. Townsend K, Evans KN, Campbell MJ *et al.* (2005) Biological actions of extra-renal 25-hydroxyvitamin D-1 α -hydroxylase and implications for chemoprevention and treatment. *J Steroid Biochem Mol Biol* **97**, 103–109.
39. Peterlik M & Cross HS (2006) Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases. *Anticancer Res* **26**, 2581–2588.
40. Cross HS, Kallay E, Farhan H *et al.* (2003) Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. *Recent Results Cancer Res* **164**, 413–425.
41. Li M & Batuman V (2009) Vitamin D: A new hope for chronic kidney disease? *Kidney Int* **76**, 1219–1221.
42. Rook GA, Steele J, Fraher L *et al.* (1986) Vitamin D₃, gamma interferon, and control of proliferation of *Mycobacterium tuberculosis* by human monocytes. *Immunology* **57**, 159–163.

43. Epstein S, Stern PH, Bell NH *et al.* (1984) Evidence for abnormal regulation of circulating $1\alpha,25$ -dihydroxyvitamin D in patients with pulmonary tuberculosis and normal calcium metabolism. *Calcif Tissue Int* **36**, 541–544.
44. Bell NH, Shary J, Shaw S *et al.* (1985) Hypercalcemia associated with increased circulating $1,25$ -dihydroxyvitamin D in a patient with pulmonary tuberculosis. *Calcif Tissue Int* **37**, 588–591.
45. Liu PT, Stenger S, Li H *et al.* (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* **311**, 1770–1773.
46. Zaiou M & Gallo RL (2002) Cathelicidins, essential gene-encoded mammalian antibiotics. *J Mol Med* **80**, 549–561.
47. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. *J Leukoc Biol* **75**, 39–48.
48. Wang TT, Nestel FP, Bourdeau V *et al.* (2004) Cutting edge: $1,25$ -Dihydroxyvitamin D_3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol* **173**, 2909–2912.
49. Gombart AF, Borregaard N & Koeffler HP (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by $1,25$ -dihydroxyvitamin D_3 . *FASEB J* **19**, 1067–1077.
50. Gombart AF, Saito T & Koeffler HP (2009) Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. *BMC Genomics* **10**, 321.
51. Adams JS, Ren S, Liu PT *et al.* (2009) Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. *J Immunol* **182**, 4289–4295.
52. Liu PT, Schenk M, Walker VP *et al.* (2009) Convergence of IL-1 β and VDR activation pathways in human TLR2/1-induced antimicrobial responses. *PLoS ONE* **4**, e5810.
53. Wang TT, Dabbas B, Laperriere D *et al.* (2010) Direct and indirect induction by $1,25$ -dihydroxyvitamin D_3 of the NOD2/CARD15-defensin $\beta 2$ innate immune pathway defective in Crohn disease. *J Biol Chem* **285**, 2227–2231.
54. Klionsky DJ & Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. *Science* **290**, 1717–1721.
55. Levine B & Deretic V (2007) Unveiling the roles of autophagy in innate and adaptive immunity. *Nat Rev Immunol* **7**, 767–777.
56. Yuk JM, Shin DM, Lee HM *et al.* (2009) Vitamin D_3 induces autophagy in human monocytes/macrophages via cathelicidin. *Cell Host Microbe* **6**, 231–243.
57. Shin DM, Yuk JM, Lee HM *et al.* Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling. *Cell Microbiol* **12**, 1648–1665.
58. Yim S, Dhawan P, Raguath C *et al.* (2007) Induction of cathelicidin in normal and CF bronchial epithelial cells by $1,25$ -dihydroxyvitamin D_3 . *J Cyst Fibros* **6**, 403–410.
59. Evans KN, Nguyen L, Chan J *et al.* (2006) Effects of 25 -hydroxyvitamin D_3 and $1,25$ -dihydroxyvitamin D_3 on cytokine production by human decidual cells. *Biol Reprod* **75**, 816–822.
60. Liu N, Kaplan AT, Low J *et al.* (2009) Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. *Biol Reprod* **80**, 398–406.
61. Schaubert J, Dorschner RA, Yamasaki K *et al.* (2006) Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. *Immunology* **118**, 509–519.
62. Schaubert J, Dorschner RA, Coda AB *et al.* (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. *J Clin Invest* **117**, 803–811.
63. Wang TT, Dabbas B, Laperriere D *et al.* (2009) Direct and indirect induction by $1,25$ -dihydroxyvitamin D_3 of the NOD2/CARD15- β defensin 2 innate immune pathway defective in Crohn's disease. *J Biol Chem* **285**, 2227–2231.
64. Brennan A, Katz DR, Nunn JD *et al.* (1987) Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D_3 metabolite, dihydroxycholecalciferol. *Immunology* **61**, 457–461.
65. Penna G & Adorini L (2000) $1\alpha,25$ -Dihydroxyvitamin D_3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J Immunol* **164**, 2405–2411.
66. Adorini L, Penna G, Giarratana N *et al.* (2003) Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. *J Cell Biochem* **88**, 227–233.
67. Penna G, Amuchastegui S, Giarratana N *et al.* (2007) $1,25$ -dihydroxyvitamin D_3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. *J Immunol* **178**, 145–153.
68. Hewison M, Freeman L, Hughes SV *et al.* (2003) Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. *J Immunol* **170**, 5382–5390.
69. Griffin MD, Lutz W, Phan VA *et al.* (2001) Dendritic cell modulation by $1,25$ dihydroxyvitamin D_3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity *in vitro* and *in vivo*. *Proc Natl Acad Sci USA* **98**, 6800–6805.
70. Panda DK, Miao D, Tremblay ML *et al.* (2001) Targeted ablation of the 25 -hydroxyvitamin D 1α -hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. *Proc Natl Acad Sci USA* **98**, 7498–7503.
71. Enioutina EY, Bareyan D & Daynes RA (2009) TLR-induced local metabolism of vitamin D_3 plays an important role in the diversification of adaptive immune responses. *J Immunol* **182**, 4296–4305.
72. Grad R (2004) Cod and the consumptive: A brief history of cod-liver oil in the treatment of pulmonary tuberculosis. *Pharm Hist* **46**, 106–120.
73. Wilkinson RJ, Llewelyn M, Toossi Z *et al.* (2000) Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. *Lancet* **355**, 618–621.
74. Ustianowski A, Shaffer R, Collin S *et al.* (2005) Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. *J Infect* **50**, 432–437.
75. Williams B, Williams AJ & Anderson ST (2008) Vitamin D deficiency and insufficiency in children with tuberculosis. *Pediatr Infect Dis J* **27**, 941–942.
76. Wejse C, Gomes VF, Rabna P *et al.* (2009) Vitamin D as supplementary treatment for tuberculosis: A double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med* **179**, 843–850.
77. Martineau AR, Wilkinson RJ, Wilkinson KA *et al.* (2007) A single dose of vitamin D enhances immunity to mycobacteria. *Am J Respir Crit Care Med* **176**, 208–213.
78. Nursyam EW, Amin Z & Rumende CM (2006) The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. *Acta Med Indones* **38**, 3–5.
79. Martineau AR, Timms PM, Bothamley GH *et al.* High-dose vitamin D_3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. *Lancet* **377**, 242–250.
80. Chun RF, Lauridsen AL, Suon L *et al.* (2010) Vitamin D-binding protein directs monocyte responses to

- 25-hydroxy- and 1,25-dihydroxyvitamin D. *J Clin Endocrinol Metab* **95**, 3368–3376.
81. Lauridsen AL, Vestergaard P, Hermann AP *et al.* (2005) Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): A cross-sectional study on 595 early postmenopausal women. *Calcif Tissue Int* **77**, 15–22.
 82. Arnaud J & Constans J (1993) Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). *Hum Genet* **92**, 183–188.
 83. Nykjaer A, Dragun D, Walther D *et al.* (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D₃. *Cell* **96**, 507–515.
 84. Jeng L, Yamshchikov AV, Judd SE *et al.* (2009) Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. *J Transl Med* **7**, 28.
 85. Gombart AF, Bhan I, Borregaard N *et al.* (2009) Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. *Clin Infect Dis* **48**, 418–424.
 86. Cannell JJ, Vieth R, Umhau JC *et al.* (2006) Epidemic influenza and vitamin D. *Epidemiol Infect* **134**, 1129–1140.
 87. Hooper LV, Stappenbeck TS, Hong CV *et al.* (2003) Angiogenins: A new class of microbicidal proteins involved in innate immunity. *Nat Immunol* **4**, 269–273.
 88. Packey CD & Sartor RB (2009) Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. *Curr Opin Infect Dis* **22**, 292–301.
 89. Masoumi A, Goldenson B, Ghirmai S *et al.* (2009) 1 α ,25-Dihydroxyvitamin D₃ interacts with curcuminoids to stimulate amyloid- β clearance by macrophages of Alzheimer's disease patients. *J Alzheimers Dis* **17**, 703–717.
 90. Stoffels K, Overbergh L, Giulietti A *et al.* (2006) Immune regulation of 25-hydroxyvitamin-D(3)-1 α -hydroxylase in human monocytes. *J Bone Miner Res* **21**, 37–47.
 91. Krutzik SR, Hewison M, Liu PT *et al.* (2008) IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. *J Immunol* **181**, 7115–7120.
 92. Edfeldt K, Liu PT, Chun R *et al.* (2010) T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. *Proc Natl Acad Sci USA* **107**, 22593–22598.
 93. Peelen E, Knippenberg S, Muris AH *et al.* (2011) Effects of vitamin D on the peripheral adaptive immune system: A review. *Autoimmun Rev*. Epubication ahead of print.
 94. Bhalla AK, Amento EP, Clemens TL *et al.* (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D₃ in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. *J Clin Endocrinol Metab* **57**, 1308–1310.
 95. Provedini DM, Tsoukas CD, Deftos LJ *et al.* (1983) 1,25-dihydroxyvitamin D₃ receptors in human leukocytes. *Science* **221**, 1181–1183.
 96. Nunn JD, Katz DR, Barker S *et al.* (1986) Regulation of human tonsillar T-cell proliferation by the active metabolite of vitamin D₃. *Immunology* **59**, 479–484.
 97. Provedini DM & Manolagas SC (1989) 1 α ,25-Dihydroxyvitamin D₃ receptor distribution and effects in subpopulations of normal human T lymphocytes. *J Clin Endocrinol Metab* **68**, 774–779.
 98. Karmali R, Hewison M, Rayment N *et al.* (1991) 1,25(OH)₂D₃ regulates c-myc mRNA levels in tonsillar T lymphocytes. *Immunology* **74**, 589–593.
 99. Lemire JM, Archer DC, Beck L *et al.* (1995) Immunosuppressive actions of 1,25-dihydroxyvitamin D₃: Preferential inhibition of Th1 functions. *J Nutr* **125**, 1704S–1708S.
 100. Overbergh L, Decallonne B, Waer M *et al.* (2000) 1 α ,25-Dihydroxyvitamin D₃ induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524–543). *Diabetes* **49**, 1301–1307.
 101. Boonstra A, Barrat FJ, Crain C *et al.* (2001) 1 α ,25-Dihydroxyvitamin D₃ has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. *J Immunol* **167**, 4974–4980.
 102. O'Kelly J, Hisatake J, Hisatake Y *et al.* (2002) Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. *J Clin Invest* **109**, 1091–1099.
 103. Harrington LE, Mangan PR & Weaver CT (2006) Expanding the effector CD4 T-cell repertoire: The Th17 lineage. *Curr Opin Immunol* **18**, 349–356.
 104. Weaver CT, Hatton RD, Mangan PR *et al.* (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* **25**, 821–852.
 105. Bettelli E, Korn T & Kuchroo VK (2007) Th17: The third member of the effector T cell trilogy. *Curr Opin Immunol* **19**, 652–657.
 106. Korn T, Oukka M, Kuchroo V *et al.* (2007) Th17 cells: Effector T cells with inflammatory properties. *Semin Immunol* **19**, 362–371.
 107. Colin EM, Asmawidjaja PS, van Hamburg JP *et al.* (2010) 1,25-dihydroxyvitamin D₃ modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. *Arthritis Rheum* **62**, 132–142.
 108. Palmer MT, Lee YK, Maynard CL *et al.* (2010) Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. *J Biol Chem* **286**, 997–1004.
 109. Chang SH, Chung Y & Dong C (2010) Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. *J Biol Chem* **285**, 38751–38755.
 110. Daniel C, Sartory NA, Zahn N *et al.* (2007) Immune modulatory treatment of TNBS colitis with calcitriol is associated with a change of a Th1/Th17 to a Th2 and regulatory T cell profile. *J Pharmacol Exp Ther* **324**, 23–33.
 111. Liu N, Nguyen L, Chun RF *et al.* (2008) Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. *Endocrinology* **149**, 4799–4808.
 112. Gorman S, Kuritzky LA, Judge MA *et al.* (2007) Topically applied 1,25-dihydroxyvitamin D₃ enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. *J Immunol* **179**, 6273–6283.
 113. Gregori S, Giarratana N, Smirolto S *et al.* (2002) A 1 α ,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. *Diabetes* **51**, 1367–1374.
 114. Mathieu C & Badenhoop K (2005) Vitamin D and type 1 diabetes mellitus: State of the art. *Trends Endocrinol Metab* **16**, 261–266.
 115. Spach KM, Nashold FE, Dittel BN *et al.* (2006) IL-10 signaling is essential for 1,25-dihydroxyvitamin D₃-mediated inhibition of experimental autoimmune encephalomyelitis. *J Immunol* **177**, 6030–6037.
 116. Jeffery LE, Burke F, Mura M *et al.* (2009) 1,25-dihydroxyvitamin D(3) and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of

- regulatory T cells expressing CTLA-4 and FoxP3. *J Immunol* **183**, 5458–5467.
117. Urry Z, Xystrakis E, Richards DF *et al.* (2009) Ligation of TLR9 induced on human IL-10-secreting Tregs by $1\alpha,25$ -dihydroxyvitamin D₃ abrogates regulatory function. *J Clin Invest* **119**, 387–398.
 118. Gregori S, Casorati M, Amuchastegui S *et al.* (2001) Regulatory T cells induced by $1\alpha,25$ -dihydroxyvitamin D₃ and mycophenolate mofetil treatment mediate transplantation tolerance. *J Immunol* **167**, 1945–1953.
 119. Dong X, Bachman LA, Kumar R *et al.* (2003) Generation of antigen-specific, interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. *Transpl Immunol* **11**, 323–333.
 120. Adorini L, Penna G, Giarratana N *et al.* (2004) Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. *J Steroid Biochem Mol Biol* **89–90**, 437–441.
 121. Willheim M, Thien R, Schratzbaumer K *et al.* (1999) Regulatory effects of $1\alpha,25$ -dihydroxyvitamin D₃ on the cytokine production of human peripheral blood lymphocytes. *J Clin Endocrinol Metab* **84**, 3739–3744.
 122. Veldman CM, Cantorna MT & DeLuca HF (2000) Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. *Arch Biochem Biophys* **374**, 334–338.
 123. Iho S, Iwamoto K, Kura F *et al.* (1990) Mechanism in $1,25(\text{OH})_2\text{D}_3$ -induced suppression of helper/suppressor function of CD4/CD8 cells to immunoglobulin production in B cells. *Cell Immunol* **127**, 12–25.
 124. Cantorna MT, Hayes CE & DeLuca HF (1996) $1,25$ -dihydroxyvitamin D₃ reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. *Proc Natl Acad Sci USA* **93**, 7861–7864.
 125. Meehan TF & DeLuca HF (2002) CD8(+) T cells are not necessary for $1\alpha,25$ -dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. *Proc Natl Acad Sci USA* **99**, 5557–5560.
 126. Yu S, Bruce D, Froicu M *et al.* (2008) Failure of T cell homing, reduced CD4/CD8 $\alpha\alpha$ intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. *Proc Natl Acad Sci USA* **105**, 20834–20839.
 127. Sigmundsdottir H, Pan J, Debes GF *et al.* (2007) DCs metabolize sunlight-induced vitamin D₃ to 'program' T cell attraction to the epidermal chemokine CCL27. *Nat Immunol* **8**, 285–293.
 128. Topilski I, Flaishon L, Naveh Y *et al.* (2004) The anti-inflammatory effects of $1,25$ -dihydroxyvitamin D₃ on Th2 cells *in vivo* are due in part to the control of integrin-mediated T lymphocyte homing. *Eur J Immunol* **34**, 1068–1076.
 129. Shiozawa K, Shiozawa S, Shimizu S *et al.* (1985) $1\alpha,25$ -Dihydroxyvitamin D₃ inhibits pokeweed mitogen-stimulated human B-cell activation: An analysis using serum-free culture conditions. *Immunology* **56**, 161–167.
 130. Provvedini DM, Tsoukas CD, Deftos LJ *et al.* (1986) $1\alpha,25$ -Dihydroxyvitamin D₃-binding macromolecules in human B lymphocytes: Effects on immunoglobulin production. *J Immunol* **136**, 2734–2740.
 131. Chen S, Sims GP, Chen XX *et al.* (2007) Modulatory effects of $1,25$ -dihydroxyvitamin D₃ on human B cell differentiation. *J Immunol* **179**, 1634–1647.
 132. Holick MF & Chen TC (2008) Vitamin D deficiency: A worldwide problem with health consequences. *Am J Clin Nutr* **87**, 1080S–1086S.
 133. Adorini L & Penna G (2008) Control of autoimmune diseases by the vitamin D endocrine system. *Nat Clin Pract Rheumatol* **4**, 404–412.
 134. Mathieu C, Gysemans C, Giulietti A *et al.* (2005) Vitamin D and diabetes. *Diabetologia* **48**, 1247–1257.
 135. Littorin B, Blom P, Scholin A *et al.* (2006) Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: Results from the nationwide Diabetes Incidence Study in Sweden (DISS). *Diabetologia* **49**, 2847–2852.
 136. Harris SS (2005) Vitamin D in type 1 diabetes prevention. *J Nutr* **135**, 323–325.
 137. Giulietti A, Gysemans C, Stoffels K *et al.* (2004) Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. *Diabetologia* **47**, 451–462.
 138. Ramos-Lopez E, Jansen T, Ivaskevicius V *et al.* (2006) Protection from type 1 diabetes by vitamin D receptor haplotypes. *Ann N Y Acad Sci* **1079**, 327–334.
 139. Bailey R, Cooper JD, Zeitels L *et al.* (2007) Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. *Diabetes* **56**, 2616–2621.
 140. Raghuwanshi A, Joshi SS & Christakos S (2008) Vitamin D and multiple sclerosis. *J Cell Biochem* **105**, 338–343.
 141. Spach KM & Hayes CE (2005) Vitamin D₃ confers protection from autoimmune encephalomyelitis only in female mice. *J Immunol* **175**, 4119–4126.
 142. Spach KM, Pedersen LB, Nashold FE *et al.* (2004) Gene expression analysis suggests that $1,25$ -dihydroxyvitamin D₃ reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. *Physiol Genomics* **18**, 141–151.
 143. Pedersen LB, Nashold FE, Spach KM *et al.* (2007) $1,25$ -dihydroxyvitamin D₃ reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. *J Neurosci Res* **85**, 2480–2490.
 144. Vagianos K, Bector S, McConnell J *et al.* (2007) Nutrition assessment of patients with inflammatory bowel disease. *JPEN J Parenter Enteral Nutr* **31**, 311–319.
 145. Pappa HM, Gordon CM, Saslowsky TM *et al.* (2006) Vitamin D status in children and young adults with inflammatory bowel disease. *Pediatrics* **118**, 1950–1961.
 146. Pappa HM, Grand RJ & Gordon CM (2006) Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. *Inflamm Bowel Dis* **12**, 1162–1174.
 147. Kong J, Zhang Z, Musch MW *et al.* (2007) Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol* **294**, 2396–2405.
 148. Froicu M & Cantorna MT (2007) Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol* **8**, 5.
 149. Froicu M, Weaver V, Wynn TA *et al.* (2003) A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. *Mol Endocrinol* **17**, 2386–2392.
 150. Lagishetty V, Misharin AV, Liu NQ *et al.* (2010) Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. *Endocrinology* **151**, 2423–2432.
 151. von Essen MR, Kongsbak M, Schjerling P *et al.* (2010) Vitamin D controls T cell antigen receptor signaling and activation of human T cells. *Nat Immunol* **11**, 344–349.
 152. Smolders J, Thewissen M & Damoiseaux J (2011) Control of T cell activation by vitamin D. *Nat Immunol* **12**, 3; author reply 3–4.